XML 45 R29.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Revenue Recognition and Accounts Receivable (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2021
Revenue from Contract with Customer [Abstract] |
Disaggregation of Revenue | The following table presents the Company’s net sales by product category for each of our reportable segments for the years ended December 31, 2021, 2020, and 2019, respectively:
(In millions) | 2021 Net Sales
Product Category | Developed Markets |  | Greater China |  | JANZ |  | Emerging Markets |  | Total
Brands | 5,759.2 |  |  | 2,207.8 |  |  | 1,197.1 |  |  | 1,677.2 |  |  | 10,841.3 |
Complex Gx and Biosimilars | 1,241.6 |  |  | 0.2 |  |  | 46.5 |  |  | 53.8 |  |  | 1,342.1 |
Generics | 3,427.9 |  |  | 4.8 |  |  | 783.8 |  |  | 1,413.7 |  |  | 5,630.2 |
Total Viatris | $ | 10,428.7 |  |  | $ | 2,212.8 |  |  | $ | 2,027.4 |  |  | $ | 3,144.7 |  |  | $ | 17,813.6 |
(In millions) | 2020 Net Sales
Product Category | Developed Markets |  | Greater China |  | JANZ |  | Emerging Markets |  | Total
Brands | 3,920.7 |  |  | 253.9 |  |  | 617.0 |  |  | 443.3 |  |  | 5,234.9 |
Complex Gx and Biosimilars | 1,202.6 |  |  | 0.7 |  |  | 42.8 |  |  | 49.4 |  |  | 1,295.5 |
Generics | 3,387.6 |  |  | 5.3 |  |  | 535.5 |  |  | 1,361.1 |  |  | 5,289.5 |
Total Viatris | $ | 8,510.9 |  |  | $ | 259.9 |  |  | $ | 1,195.3 |  |  | $ | 1,853.8 |  |  | $ | 11,819.9 |
(In millions) | 2019 Net Sales
Product Category | Developed Markets |  | Greater China |  | JANZ |  | Emerging Markets |  | Total
Brands | 4,199.1 |  |  | 207.6 |  |  | 533.3 |  |  | 422.1 |  |  | 5,362.1 |
Complex Gx and Biosimilars | 1,127.4 |  |  | 0.4 |  |  | 23.8 |  |  | 59.7 |  |  | 1,211.3 |
Generics | 2,913.5 |  |  | 6.6 |  |  | 635.4 |  |  | 1,241.4 |  |  | 4,796.9 |
Total Viatris | $ | 8,240.0 |  |  | $ | 214.6 |  |  | $ | 1,192.5 |  |  | $ | 1,723.2 |  |  | $ | 11,370.3 |
The following table presents net sales on a consolidated basis for select key products for the year ended December 31, 2021:
(In millions) |  |  |  | Year Ended December 31, 2021
Select Key Global Products |  |  |  |
Lipitor ® |  |  |  | $ | 1,663.2 |
Norvasc ® |  |  |  | 824.7 |
Lyrica ® |  |  |  | 728.5 |
Viagra ® |  |  |  | 533.8 |
EpiPen® Auto-Injectors |  |  |  | 391.7 |
Celebrex ® |  |  |  | 344.4 |
Effexor ® |  |  |  | 316.8 |
Creon ® |  |  |  | 309.8 |
Zoloft ® |  |  |  | 284.3 |
Xalabrands |  |  |  | 226.0 |
Select Key Segment Products |  |  |  |
Influvac ® |  |  |  | $ | 299.3 |
Amitiza ® |  |  |  | 201.5 |
Xanax ® |  |  |  | 185.9 |
Dymista ® |  |  |  | 168.0 |
Yupelri ® |  |  |  | 161.9 |
____________ (a)The Company does not disclose net sales for any products considered competitively sensitive. (b)Products disclosed may change in future periods, including as a result of seasonality, competition or new product launches. (c)Prior periods are not presented due to significance of products acquired as part of the Combination. The following is a rollforward of the categories of variable consideration during 2021:
(In millions) | Balance at December 31, 2020 |  | Current Provision Related to Sales Made in the Current Period |  | Measurement Period Adjustments and Reclasses |  | Checks/ Credits Issued to Third Parties |  | Effects of Foreign Exchange |  | Balance at December 31, 2021
Chargebacks | $ | 585.2 |  |  | $ | 5,530.1 |  |  | $ | 63.4 |  |  | $ | (5,585.4) |  |  | $ | (1.6) |  |  | $ | 591.7 |
Rebates, promotional programs and other sales allowances | 1,576.3 |  |  | 6,135.6 |  |  | (57.6) |  |  | (6,267.1) |  |  | (14.2) |  |  | 1,373.0 |
Returns | 539.9 |  |  | 384.6 |  |  | 269.0 |  |  | (499.0) |  |  | (7.7) |  |  | 686.8 |
Governmental rebate programs | 313.3 |  |  | 689.5 |  |  | 110.6 |  |  | (705.2) |  |  | (9.0) |  |  | 399.2 |
Total | $ | 3,014.7 |  |  | $ | 12,739.8 |  |  | $ | 385.4 |  |  | $ | (13,056.7) |  |  | $ | (32.5) |  |  | $ | 3,050.7 |
Schedule of Accounts Receivable, Net | Accounts receivable are presented net of allowances relating to these provisions, which were comprised of the following at December 31, 2021 and 2020, respectively:
(In millions) | December 31, 2021 |  | December 31, 2020
Accounts receivable, net | $ | 1,688.6 |  |  | $ | 1,802.9 |
Other current liabilities | 1,362.1 |  |  | 1,211.8 |
Total | $ | 3,050.7 |  |  | $ | 3,014.7 |

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.3,4) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration